Ottonomy raises Series A from Japan's Enrission to scale hospital delivery robots
What's the deal? Ottonomy IODealroom has a profile for this one. Try Dealroom →, a US maker of autonomous delivery robots, has raised a Series A round from Japanese venture capital firm Enrission India CapitalDealroom has a profile for this one. Try Dealroom →. The investment, announced in November 2026, came through Enrission's "Enrission SP26 India" fund. Terms were not disclosed.
What does Ottonomy do? Founded in 2020 and based in Santa Monica, California, the company builds "Ottobot" robots that move goods seamlessly across indoor and outdoor environments. Its "context AI" combines video recognition, ultrasonic sensors, and edge computing to navigate where GPS fails, while API links to elevator controllers let it travel across multiple floors unmanned.
Why now? US hospitals face chronic nursing shortages, with more than 300,000 nurses projected to be short nationwide by 2036. Nurses reportedly spend about half their time on non-clinical tasks such as moving supplies — a gap Ottonomy aims to fill with automation.
What's the endgame? The company centres its business on medical facilities, with deployments at US health systems and global firms. It plans to expand further in healthcare, enter new global markets, and launch software to manage multiple robots at once.
Not its first backer. Ottonomy has drawn outside capital before. In September 2026, Nasdaq-listed Gix InternetDealroom has a profile for this one. Try Dealroom → announced a $500,000 investment via a SAFE, plus a non-binding proposal that could eventually give Gix a majority stake. Its hospital work includes an operating system, built with Arrive AI, for moving medical supplies and lab samples at Hancock Regional HospitalDealroom has a profile for this one. Try Dealroom →.
The signal: The round is a follow-on bet on a company with existing pilots rather than an untested idea. With labour shortages hitting both US and Japanese healthcare, investors are backing "physical AI" as potential infrastructure for medical and industrial logistics — though the deal discloses no amount, valuation, or evidence of broad commercial scale.
Read more: prtimes.jp
Image credit: Generated with Gemini
